TMO Quantitative Stock Analysis

Thermo Fisher Scientific (TMO) received a 66% rating from Validea's guru fundamental report using Partha Mohanram's P/B Growth Investor model, which targets low book-to-market stocks with sustained growth. While the large-cap medical equipment stock passed key financial health metrics like return on assets and cash flow, it notably failed criteria related to advertising, capital expenditures, and research and development as a percentage of assets, falling short of the 80%+ threshold typically indicating strategic interest.

Analysis

Thermo Fisher Scientific (TMO) receives a lukewarm assessment from Validea's P/B Growth Investor model, scoring 66%, which is notably below the 80% threshold that indicates strategic interest. The analysis reveals a significant dichotomy in TMO's profile. On one hand, the company demonstrates strong fundamental health, passing criteria for its book-to-market ratio, return on assets (ROA), and cash flow from operations relative to assets. Furthermore, it exhibits stability, evidenced by passing grades for variance in both ROA and sales. However, for a model designed to identify sustained future growth, TMO fails on three critical forward-looking metrics: advertising to assets, capital expenditures to assets, and research and development to assets. This suggests that while TMO is a fundamentally sound and profitable large-cap, its current levels of investment in key growth-driving activities are insufficient to meet the rigorous criteria of this specific academic growth strategy.

Key Decisions for Investors

• Growth-focused investors should note that TMO's score of 66% and its failure on R&D and capex metrics signal that it may not align with strategies seeking aggressive, high-growth profiles.
• Investors with a value or GARP (Growth at a Reasonable Price) orientation might view the strong fundamentals, particularly the positive return on assets and robust cash flow, as an indicator of a quality, stable business despite the low growth-investment signals.
• Monitor future capital allocation announcements and quarterly reports for any changes in spending on R&D and capital expenditures, as an increase could alter the company's growth trajectory and its attractiveness under this type of model.